Publications by authors named "Mariana Isabel Canaro Hirnyk"
Article Synopsis
- Avatrombopag is a newly approved treatment for immune thrombocytopenia (ITP), with limited real-world effectiveness and safety data available.
- A study by the Spanish ITP Group involving 268 patients showed that 90.1% of those with low platelet counts improved significantly after starting the drug, with many achieving stable platelet levels.
- The treatment allowed most patients to reduce or stop corticosteroid use, and only a small percentage experienced thrombocytosis or thromboembolic events, indicating its potential as an effective management option for ITP.
Prophylaxis with the blood clotting factor, factor VIII (FVIII) is ineffective for individuals with haemophilia A and high-titre inhibitors to FVIII. Prophylaxis with the FVIII bypassing agents activated prothrombin complex concentrates (aPCC; FEIBA® Baxalta) or recombinant activated factor VII (rFVIIa; Novo-Seven®, Novo Nordisk) may be an effective alternative. It was our aim to develop evidence -and expert opinion- based guidelines for prophylactic therapy for patients with high-titre inhibitors to FVIII.
View Article and Find Full Text PDFIntroduction: Patients with severe haemophilia and inhibitors against factor VIII who require surgery need a prophylactic approach to prevent bleeding complications. Scientific evidence to decide the best prophylactic treatment is very limited and mainly based on retrospective or case series.
Aims: To develop evidence- and expert opinion-based guidelines for prophylactic therapy for patients with haemophilia and inhibitors undergoing surgery.